Romero Fernandez J, Cordoba Largo S, Benlloch Rodriguez R, Gil Haro B
Cancers (Basel). 2024; 16(16).
PMID: 39199577
PMC: 11352652.
DOI: 10.3390/cancers16162804.
Yuan J, Zhang M, Wang M, Zhang M, Wu K, Chen H
Sci Rep. 2024; 14(1):9208.
PMID: 38649431
PMC: 11035569.
DOI: 10.1038/s41598-024-59961-0.
Tojjari A, Yu J, Saeed A
Cancers (Basel). 2024; 16(5).
PMID: 38473415
PMC: 10930975.
DOI: 10.3390/cancers16051058.
Maita K, Torres-Guzman R, Avila F, Garcia J, Rinker B, Ho O
Ann Transl Med. 2024; 11(12):417.
PMID: 38213815
PMC: 10777226.
DOI: 10.21037/atm-23-1052.
Kasena A, Antonio F
Health SA. 2024; 28:2245.
PMID: 38204863
PMC: 10778377.
DOI: 10.4102/hsag.v28i0.2245.
The application, safety, and future of immune cell therapies and prognosis in different malignancies.
Einloth K, Gayfield S, McMaster T, Didier A, Dworkin L, Creeden J
Bioimpacts. 2023; 13(6):439-455.
PMID: 38022382
PMC: 10676524.
DOI: 10.34172/bi.2023.27521.
Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers.
Zhao D, Mo Y, Neganova M, Aleksandrova Y, Tse E, Chubarev V
Front Cell Dev Biol. 2023; 11:1266537.
PMID: 37849740
PMC: 10577389.
DOI: 10.3389/fcell.2023.1266537.
Astragaloside IV protects LO2 cells from oxidative damage caused by radiation-induced bystander effect through Akt/Nrf2 pathway.
Wan D, Zhu Z, Zhou J, Deng Z, Lei P, Liu Q
Toxicol Res (Camb). 2023; 12(4):635-647.
PMID: 37663802
PMC: 10470369.
DOI: 10.1093/toxres/tfad048.
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
Kumar R, Kim J, Deek M, Eskander M, Gulhati P, In H
Curr Oncol. 2023; 30(7):6432-6446.
PMID: 37504333
PMC: 10378032.
DOI: 10.3390/curroncol30070473.
New treatment insights into pancreatic acinar cell carcinoma: case report and literature review.
Zhao F, Yang D, Xu T, He J, Guo J, Li X
Front Oncol. 2023; 13:1210064.
PMID: 37465113
PMC: 10351044.
DOI: 10.3389/fonc.2023.1210064.
Immunomodulatory Macrophages Enable E-MNC Therapy for Radiation-Induced Salivary Gland Hypofunction.
Honma R, I T, Seki M, Iwatake M, Ogaeri T, Hasegawa K
Cells. 2023; 12(10).
PMID: 37408251
PMC: 10216929.
DOI: 10.3390/cells12101417.
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Mukherjee D, Romano E, Walshaw R, Zeef L, Banyard A, Kitcatt S
Oncoimmunology. 2023; 12(1):2223094.
PMID: 37332616
PMC: 10274532.
DOI: 10.1080/2162402X.2023.2223094.
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Chen L, Wei A, Shu C
Ther Adv Med Oncol. 2023; 15:17588359231163798.
PMID: 37007633
PMC: 10052589.
DOI: 10.1177/17588359231163798.
Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literature.
Civil Y, Jonker L, Groot Koerkamp M, Duvivier K, de Vries R, Oei A
Ann Surg Oncol. 2023; 30(6):3263-3279.
PMID: 36869253
PMC: 10175515.
DOI: 10.1245/s10434-023-13233-9.
Identification of S100A9 as a Potential Inflammation-Related Biomarker for Radiation-Induced Lung Injury.
Liu Y, Wu M, Guo J, Tang Y, Jiang H, Yang B
J Clin Med. 2023; 12(3).
PMID: 36769382
PMC: 9917937.
DOI: 10.3390/jcm12030733.
Harnessing immunomodulation during DNA damage in Ewing sarcoma.
Daley J, Olson A, Bailey K
Front Oncol. 2022; 12:1048705.
PMID: 36483025
PMC: 9722957.
DOI: 10.3389/fonc.2022.1048705.
Glutamine metabolism and radiosensitivity: Beyond the Warburg effect.
Alden R, Kamran M, Bashjawish B, Simone B
Front Oncol. 2022; 12:1070514.
PMID: 36465373
PMC: 9712788.
DOI: 10.3389/fonc.2022.1070514.
Monocyte programming by cancer therapy.
Patysheva M, Frolova A, Larionova I, Afanasev S, Tarasova A, Cherdyntseva N
Front Immunol. 2022; 13:994319.
PMID: 36341366
PMC: 9631446.
DOI: 10.3389/fimmu.2022.994319.
Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.
Zhang Y, Xu Z, Chen H, Sun X, Zhang Z
Sci Rep. 2022; 12(1):14288.
PMID: 35995985
PMC: 9395522.
DOI: 10.1038/s41598-022-18251-3.
The dark side of immunotherapy: pancreatic cancer.
Mucciolo G, Roux C, Scagliotti A, Brugiapaglia S, Novelli F, Cappello P
Cancer Drug Resist. 2022; 3(3):491-520.
PMID: 35582441
PMC: 8992483.
DOI: 10.20517/cdr.2020.13.